South Korea
· Delayed Price · Currency is KRW ISU Abxis Company Description
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.
The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease.
It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease.
The company was formerly known as Petagen Co., Ltd. and changed its name to ISU Abxis Co., Ltd. in November 2004.
ISU Abxis Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea.
| Country | South Korea |
| Founded | 2001 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 95 |
| CEO | Yeob Hwang |
Contact Details
Address: Global R&D Center, Building C Seongnam-si, 13488 South Korea | |
| Phone | 82 3 1696 4700 |
| Website | abxis.com |
Stock Details
| Ticker Symbol | 086890 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yeob Hwang | Chief Executive Officer |